Mereo BioPharma Group PLC (MREO) intrinsic value & 10-year financials
Mereo BioPharma Group PLC (MREO) has a Graham intrinsic value of $6.33 per share. At $0.30 on Oct 17, 2026, the stock trades 95% below that value. Over the last 5 fiscal years revenue shrank 77.6% a year to $500.0K, with an average return on invested capital of 544.9%.
- Graham intrinsic value
- $6.33
- Share price (Oct 17, 2026)
- $0.30
- Price vs Graham value
- 95% below
- Market cap
- $241.5M
- Revenue (FY2025)
- $500.0K
- Revenue growth (5-yr CAGR)
- -77.6%
- ROIC (10-yr avg)
- 544.9%
- Free cash flow (FY2025)
- -$31.0M
MREO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $500.0K | -$41.9M | -$0.05 | -$31.0M | -8021.4% | 919.7% |
| FY2024 | $0 | -$43.3M | -$0.06 | -$32.8M | — | 647.8% |
| FY2023 | $10.0M | -$29.5M | -$0.04 | -$21.1M | -284.2% | 262.3% |
| FY2022 | $0 | -$42.2M | -$0.07 | -$48.8M | — | 349.8% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Mereo BioPharma Group plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Mereo BioPharma Group plc has historically struggled to out-earn its cost of capital, averaging just 5.4% ROIC.
Mereo BioPharma Group plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Mereo BioPharma Group plc is modeled at -77.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $6.33 per share.